贝伐珠单抗联合胸腺法新治疗NSCLC合并MPE的疗效及其机制  

Clinical efficacy of bevacizumab and thymalfasin therapy in the treatment of lung cancer-related malignant pleural effusion and its mechanism

作　　者：卢瑞琦[1] 郭昌[1] 孙燕川 杨泽西 王利欢 徐海亮 崔立亚 宋建民[1] LU Ruiqi;GUO Chang;SUN Yanchuan;YANG Zexi;WANG Lihuan;XU Hailiang;CUI Liya;SONG Jianmin(Department of Respiration,Baoding First Central Hospital,Baoding 071000,Hebei,China)

机构地区：[1]保定市第一中心医院呼吸1科,河北保定071000

出　　处：《中南医学科学杂志》2020年第5期484-486,527,共4页Medical Science Journal of Central South China

摘　　要：探讨贝伐珠单抗联合胸腺法新治疗非小细胞型肺癌(NSCLC)合并恶性胸腔积液(MPE)的疗效及化疗耐药性的影响。选取80例本科室收治的NSCLC合并MPE患者的病例资料,根据治疗方式分为对照组(采用常规治疗)和研究组(采用在常规治疗基础上联合贝伐珠单抗及胸腺法新治疗),每组40例。结果显示,与对照组比较,研究组患者的临床有效率显著增高,相关血清指标显著降低,RRM1表达水平显著降低。结果说明,在常规治疗的基础上,贝伐珠单抗联合胸腺法新可显著提高NSCLC合并MPE患者的治疗效果,其机制可能与改善机体免疫功能,可降低耐药性有关。To investigate the efficacy of bevacizumab combined with thymalfasin in the treatment of non-small cell lung cancer(NSCLC)with malignant pleural effusion(MPE),the cases of 80 patients with NSCLC and MPE in our department were selected and divided into study group and control group according to the treatment method(n=40).The patients in control group were given traditional treatment and patients in study group were given traditional treatment plus bevacizumab and thymalfasin.The results showed,compared to the control group,the study group has a higher clinical effective rate,lower immune indexes,and a lower RRM1.In conclusion,combination of bevacizumab and thymus can improve the curative effect of NSCLC with MPE on the basic traditional therapy,the mechanism is related to that improving the immune function of the body can reduce the resistance to systemic treatment.

关 键 词：贝伐珠单抗 胸腺法新 非小细胞肺癌 恶性胸腔积液 疗效 

分 类 号：R734.2[医药卫生—肿瘤]